Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.39 |
| ▸ | BCL6 | P41182 | 4/20 | 0.37 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.37 |
| ▸ | STK17B | O94768 | 1/20 | 0.36 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18995059 | 0.84 | EGFR (0.41) | EGFRERBB2BCL6PTK6STK17B | |
| SCHEMBL18995005 | 0.83 | BCL6 (0.41) | EGFRBCL6STK17BSTK17ASYK | |
| SCHEMBL19836217 | 0.72 | MRGPRX4 (0.40) | — | |
| SCHEMBL29352285 | 0.71 | BCL6 (0.61) | BCL6STK17BSTK17ASYKNCOR2 | |
| SCHEMBL2103566 | 0.71 | BCL6 (0.59) | EGFRERBB2BCL6STK17ASYK | |
| SCHEMBL19527786 | 0.71 | CTSL (0.38) | — | |
| SCHEMBL18995012 | 0.71 | BCL6 (0.43) | EGFRBCL6STK17BSTK17ASYK | |
| SCHEMBL3973068 | 0.70 | ERBB2 (0.62) | EGFRERBB2PTK6GRM4 | |
| SCHEMBL18994542 | 0.69 | RXRA (0.43) | — | |
| SCHEMBL4092866 | 0.69 | EGFR (0.63) | EGFRERBB2PTK6GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2018-02-01 | — | — | US | disclosed |
| US-9682976-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | PRKCH, PRKCA, PRKCB | EGFR 2299/4885ERBB2 703/4885BCL6 1014/4885 |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | EGFR 2299/4885ERBB2 703/4885BCL6 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.